Table 4

Progression-Free survival for the overall real-world cohort and GARNET cohort (before and after matching)

	Overall real-world cohort (n=999)	GARNET (dostarlimab) cohort
	Overall real-world cohort (n=999)	Before matching (n=153)	Scenario 1 (ESS=18)	Scenario 2 (ESS=62)	Scenario 3 (ESS=67)
	PFS (TTNT as proxy)
Median PFS, months (95% CI)	7.7 (7.1 to 8.2)	8.3 (4.2 to 18.0)	4.2 (2.7 to 16.6)	8.1 (4.2 to 37.3)	13.8 (5.2 to 37.3)
PFS rate (95% CI)
6 months	0.61 (0.58 to 0.64)	0.51 (0.43 to 0.59)	0.45 (0.23 to 0.64)	0.53 (0.39 to 0.64)	0.60 (0.47 to 0.70)
12 months	0.28 (0.25 to 0.31)	0.48 (0.40 to 0.56)	0.37 (0.19 to 0.56)	0.49 (0.36 to 0.61)	0.54 (0.42 to 0.66)
18 months	0.16 (0.14 to 0.19)	0.43 (0.34 to 0.51)	0.32 (0.16 to 0.50)	0.42 (0.29 to 0.54)	0.43 (0.30 to 0.56)
	PFS (TTD as proxy)
Median PFS, months (95% CI)	3.4 (3.2 to 3.4)	8.3 (4.2 to 18.0)	4.2 (2.7 to 16.6)	8.1 (4.2 to 37.3)	13.8 (5.2 to 37.3)
PFS rate (95% CI)
6 months	0.12 (0.10 to 0.15)	0.51 (0.43 to 0.59)	0.45 (0.23 to 0.64)	0.53 (0.39 to 0.64)	0.60 (0.47 to 0.70)
12 months	0.02 (0.01 to 0.03)	0.48 (0.40 to 0.56)	0.37 (0.19 to 0.56)	0.49 (0.36 to 0.61)	0.54 (0.42 to 0.66)
18 months	-^†	0.43 (0.34 to 0.51)	0.32 (0.16 to 0.50)	0.42 (0.29 to 0.54)	0.43 (0.30 to 0.56)

Scenario 1: Matching variables are histology, grade, and number of prior platinum-based therapies; scenario 2: Matching variables are histology and number of prior platinum-based therapies; scenario 3: Matching variables are race, histology, stage at initial diagnosis, and surgery (ECOG PS was not included as a matching variable due to patients with unknown status).
*No more patients at risk.
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ESS, effective sample size; PFS, progression-free survival; TTD, time-to-discontinuation; TTNT, time-to-next treatment.